Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03507374 · ClinicalTrials.gov registry record · Early Phase 1
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
A Early Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03507374 is a Early Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 20 participants.
The verdict
NCT03507374, a Early Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and intracranial atherosclerotic disease are randomized to either drug or placebo.
Interventions
- DRUG Placebo
- DRUG Alirocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2020-04-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03507374
The ClinicalTrials.gov registry entry for NCT03507374 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03507374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03507374 about?
NCT03507374 is a clinical study titled "PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis". This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and intracranial atherosclerotic disease are randomized to either drug or placebo.
What is the current status of trial NCT03507374?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2018-10-30. Estimated completion is 2020-04-17.
What interventions are being tested in trial NCT03507374?
The interventions under investigation include: Placebo (DRUG), Alirocumab (DRUG).
Who is sponsoring clinical trial NCT03507374?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.